PDE-4 Inhibition in Sarcoidosis Patients: A Retrospective Single-Center Analysis of 51 Patients.

ABSTRACT: Background: Several sarcoidosis patients require treatment with corticosteroids to prevent organ damage and control symptoms. However, corticosteroids are associated with numerous side effects and can be detrimental to patients if used long-term. Roflumilast is approved for the treatment of chronic obstructive pulmonary disease (COPD) and has been studied with positive results in patients with fibrosing sarcoidosis. Due to its mode of action, it targets proinflammatory and profibrotic pathways involved in sarcoidosis and could be a suitable medication for sarcoidosis. Methods: We retrospectively analyzed a cohort of 51 sarcoidosis patients treated with Roflumilast off-label between 2010 and 2020 at the Department of Pneumology, University Hospital Freiburg. Medical records, l

SUBMITTER: Feineis ME 

PROVIDER: S-EPMC12654997 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature